The stock of Edwards Lifesciences Corp (NYSE:EW) reached all time high today, Oct, 11 and still has $146.74 target or 22.00% above today’s $120.28 share price. This indicates more upside for the $25.88 billion company. This technical setup was reported by Barchart.com. If the $146.74 PT is reached, the company will be worth $5.69B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 63,944 shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has risen 42.58% since March 8, 2016 and is uptrending. It has outperformed by 33.26% the S&P500.
Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on October, 24. They expect $0.67 earnings per share, up 24.07% or $0.13 from last year’s $0.54 per share. EW’s profit will be $144.16 million for 44.88 P/E if the $0.67 EPS becomes a reality. After $0.76 actual earnings per share reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts -11.84% negative EPS growth.
Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage
Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 18 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 72% are positive. $195 is the highest target while $86 is the lowest. The $115.12 average target is -4.29% below today’s ($120.28) stock price. Edwards Lifesciences Corp has been the topic of 49 analyst reports since July 30, 2015 according to StockzIntelligence Inc. As per Friday, January 8, the company rating was initiated by SunTrust. The company was initiated on Tuesday, September 22 by UBS. Suntrust Robinson initiated Edwards Lifesciences Corp (NYSE:EW) on Friday, January 8 with “Neutral” rating. The stock has “Buy” rating given by BTIG Research on Wednesday, July 27. The stock of Edwards Lifesciences Corp (NYSE:EW) earned “Market Perform” rating by Northland Capital on Tuesday, April 5. Barclays Capital maintained Edwards Lifesciences Corp (NYSE:EW) on Thursday, April 7 with “Equal-Weight” rating. The rating was maintained by Leerink Swann on Monday, April 4 with “Outperform”. The rating was reinitiated by Credit Suisse with “Outperform” on Monday, August 10. The firm has “Overweight” rating by JP Morgan given on Monday, April 4. The rating was initiated by Cowen & Co with “Outperform” on Friday, October 9.
According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”
More recent Edwards Lifesciences Corp (NYSE:EW) news were published by: Marketwatch.com which released: “Edwards Lifesciences Corp stock up 2% after two heart valves approved for more …” on August 18, 2016. Also Wsj.com published the news titled: “Edwards Lifesciences Raises 2016 View as Earnings, Revenue Top Estimates” on April 26, 2016. Fool.com‘s news article titled: “Why Edwards Lifesciences Shares Are Surging 17% Today” with publication date: April 04, 2016 was also an interesting one.
EW Company Profile
Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.